Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nesiritide: a unique therapeutic cardiac peptide.

B K Rayburn1, R C Bourge

  • 1University of Alabama at Birmingham, Birmingham, AL, USA.

Reviews in Cardiovascular Medicine
|November 20, 2002
PubMed
Summary

Nesiritide, a recombinant human B-type natriuretic peptide, offers a new treatment for heart failure. It provides safe and effective hemodynamic improvements, including vasodilation and natriuresis, for managing decompensated congestive heart failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.

Pulmonary circulation·2016
Same author

Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole.

Transplant infectious disease : an official journal of the Transplantation Society·2012
Same author

Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2006
Same author

Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2006
Same author

To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2005
Same author

Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study.

The Journal of thoracic and cardiovascular surgery·2003

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Congestive heart failure (CHF) is a complex condition requiring novel therapeutic agents.
  • Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP).
  • BNP plays a crucial role in cardiovascular homeostasis.

Purpose of the Study:

  • To review the physiology and pathophysiology of natriuretic peptides.
  • To evaluate the clinical data, hemodynamic effects, efficacy, and safety of nesiritide in heart failure treatment.

Main Methods:

  • Review of existing literature on natriuretic peptides and nesiritide.
  • Analysis of clinical trial data regarding nesiritide's impact on heart failure patients.
  • Critique of hemodynamic effects, efficacy, and safety profiles.

Main Results:

  • Nesiritide exhibits balanced arterial and venous vasodilatation.
  • The drug promotes significant natriuresis and diuresis.
  • Clinical data suggests nesiritide is a safe and effective option for heart failure management.

Conclusions:

  • Nesiritide represents a novel therapeutic peptide class for heart failure.
  • It offers unique and safe hemodynamic properties for managing decompensated CHF.
  • Nesiritide shows promise as an important agent in cardiovascular pharmacotherapy.

Related Experiment Videos